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Introduction 
 Venous system is very different 
and more complex than arterial 
system. To deliver blood against the 
forces of gravity, venous system rely 
on valve function and peripheral 
muscle pump. In acute venous 
disease, blood becomes stasis and 
leads to deep vein thrombosis. In 
chronic condition, clinical 
manifestation may vary from either 
venous obstruction or vascular 
incompetence. In general venous 
diseases are devided into venous 
thromboembolism and chronic venous 
insufficiency. 
When it comes to venous 
diseases, clinicians, especially in 
Indonesia, tend to pay less attention 
and effort to make diagnosis, let alone 
to manage them. Veins are less 
understood affairs in cardiovascular 
yet fortunately, venology and 
endovascular field see rapid 
development in order to catch up with 
increasing incidence of venous 
disease. 
 Enormous burden have been 
placed in the shoulder of our society 
whether in economic, physical, and 
mental aspects. Lower extremities 
venous disease is one of the most 
prevalent cases. In certain 
circumstances it will develop into more 
life-threatening (acute pulmonary 
embolism) or limb-threatening venous 
ischemia (such as in phlegmasia 
cerulia dolens).  While many questions 
remain more considerable than their 
answers, plentiful progress has been 
made in our acknoledgement of the 
disease and how or when to do the 
intervention. Many techniques have 
been invented and perfected to 
minimize bleeding and remove 
thrombus from the vein. Endovascular 
recanalization is now comparable 
against open surgery with much lower 
complications. 
 
Venous thromboembolism (VTE) 
A VTE is the third most 
common cardio-cerebro-vascular 
disease in the world after acute 
myocardial infarction and 
cerebrovascular disease (stroke).  
VTE consists of two main disease i.e. 
deep vein thrombosis (DVT) and 
pulmonary embolism (PE).1   
 Clinical manifestation of DVT of 
the legs are swelling or pitting edema, 
erythema, pain, and the presence of 
collateral superficial veins that would 
be well presented with duplex 
ultrasound as its main modality of 
diagnosis.2 
 The most life-threatening 
complication of DVT is pulmonary 
embolism because of its significant 
case mortality rate. Historically, 
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recommendation of treatment for DVT 
was to prevent pulmonary embolism 
using anticoagulant drugs.Initial 
therapy with means of parenteral 
anticoagulation drug (unfractionated 
heparin, low-molecular-weight heparin, 
or fondaparinux) bridging to long term 
anti-vitamin K. Of course this practice 
was highly inconvenient because of 
drug interaction and troublesome 
monitoring. Thus, direct oral 
anticoagulation drugs such as 
rivaroxaban, apixaban, and dabigatran 
emerged to be drug of choices 
because its pharmacokinetics highly 
unaffected by diet with comparable 
efficacy in the prevention of recurrent 
VTE against anti-vitamin K drug. 
However, no antidote exists today to 
prevent serious bleeding caused by 
these drugs.3,4  
 
Post thrombotic syndrome (PTS)  
Modernization of concept 
beyond pulmonary embolism 
prevention has been suggested by 
contemporary studies. Post-thrombotic 
syndrome (PTS) is a gruesome 
condition that develop in approxima-
tely 40% patients with DVT. It can be 
felt until years after first diagnosed 
DVT. The symptoms of PTS are 
venous claudiation, fatigue, heaviness, 
and swelling that worsens with upright 
position and activities. VETO trials 
(Venous Thrombosis Outcomes) 
stated that PTS are the main 
predictors of patients quality of life 2 
years after first diagnosed DVT.5  
 The PTS pathogenesis is still 
unclear. Initial inflammatory response 
to thrombosis affects the resolution, 
organization of thrombus, and injury of 
the vein wall. Loss of wall compliance, 
increase of wall thickness, and 
impaired vessel valvular function are 
the result of this mechanism. Vein 
thrombosis should be cleared from the 
deep venous system because inability 
to resolve it will block venous blood 
flow and do the damages of the 
venous valves as well as alters the 
adjacent vein wall.6 
 Rapid thrombus resolution and 
restoration of the flow in deep vein 
after thrombosis is the key to prevent 
PTS thus creating "open vein 
hypothesis". PTS predilection is in the 
proximal DVT patient who still had 
thrombus in the vein after 6 months.7 
There are strong correlation between 
the size of residual thrombus after 
treatment with anticoagulant and the 
incidence of recurrent VTE, hence the 
development of PTS. Several studies 
proposed usage of systemic 
thrombolysis to clear the thrombus. 
Nevertheless, significant lysis 
happened in patient with 
nonobstructive thrombi instead of 
obstructive. This demonstrated that 
systemic administration cannot reach 
the target adequately. On the other 
hand, intrathrombus infusion of 
thrombolytic drugs has shown greater 
efficacy and maintained lower risk of 
bleeding. This principle gives rise to 
the current catheter-directed 
thrombolytic DVT therapy.8 
 
Catheter-directed thrombolysis 
(CDT) 
Systemic thrombolytic is not 
recommended for DVT therapy, only 
CDT is suggested. In DVT, 
endovascular treatment through 
catheter directed therapy is more 
acceptable than systemic 
administration, The reason is because 
of the increase of bleeding risk in 
systemic thrombolysis than using 
CDT. CDT delivers rapid and direct 
infusion of thrombolytic agent through 
fenestrated catheter so high local 
doses of drug even with reduced dose 
of systemic lytic agent within the 
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thrombosed location, increase 
possibility to reduce clot and repair 
vessel patency and less major 
bleeding events.9  
A CDT delivers more 
concentrated drug into target site while 
reducing drug dosage. It was the first 
endovascular thrombolytic method to 
treat DVT. The best way to reach 
target vein is using vessels caudal to 
the thrombus and placing the tip of the 
catheter inside it. If the popliteal vein is 
patent, we can puncture it through this 
vein. However, if this vein is also 
occluded, we can use the fibularis vein 
or posterior tibial vein although 
superior skill is needed. Internal 
jugular vein or brachial vein using 
longer catheters and wires can also be 
considered. Catheters used in this 
practice are multi-side-hole catheter 
attached within the thrombus. 
Recombinant tissue plasminogen 
activator (0.01mg/kg/h up to 1 mg/h) is 
typically continued for 6-24 hours while 
patient is monitored for bleeding. 
Laboratory parameters such as 
fibrinogen, partial thromboplastin time, 
and fibrinogen level can be drawn 
every 6 hours.10 
The onset of DVT is associated 
with successful treatment. CDT is 
probably to be successful in acute 
condition when onset is less than 14 
days, while in subacute condition 
(between 14-28 days) is still beneficial 
in some studies. However, when the 
onset is more than 28 days, CDT 
successful is questionable.11  
 
Percutaneus transluminal 
angioplasty (PTA) 
Evaluation venography is 
perfomed to see the remaining 
thrombus and position of the catheter. 
If thrombus is still persist, percutaneus 
transluminal angioplasty (PTA) using 
balloon angioplasty can be done to 
increase surface area for thrombolysis 
and the infusion is continued. Stent 
placement are generally reserved for 
the large iliofemoral obstruction with 
good results.8 Routine use of inferior 
vena cava deemed unnecessary as 
pulmonary embolism complication of 
CDT is very low (1.3%).12  
 With the advancement of 
technology in endovascular 
interventions, there are several 
techniques which could increase the 
efficacy of CDT such as combining 
percutaneous mechanical thrombec-
tomy (PMT) with CDT. Pharmaco-
mechanical catheter directed 
thrombolysis (PCDT) enhance 
intervensionist ability to perform large 
thrombus removal in patient with DVT. 
It can increase thrombus surface area, 
accelerate pharmacologic thrombo-
lysis, reduce drug dose and duration, 
as well as reduce bleeding 
complications and risk of pulmonary 
embolism.13  
 
Angio Jet 
Angio Jet is a pulse-spray 
bolus dose of thrombolytic drug 
directly into the thrombus then the 
AngioJet catheter is used to aspirate 
the residual thrombus. The 
effectivenes of therapy can be reach in 
80-90% of patients, half of it may be 
trated in single session.14  
 Catheter-directed thrombolysis 
is indicated in patient with extensive 
thrombosis with high risk of developing 
pulmonary embolism, proximal DVT 
(iliofemoral or femoral vein), 
threatened limb viability such as in 
phelgmasiacerulia dolens, good 
physicological reserve, recent onset of 
symptoms less than 14 days, with life 
expectancy more than 6 months, and 
absence of contraindications to 
thrombolysis.15  
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Thrombolysis for pulmonary 
embolism (PE) 
A PE is the most fatal 
complication of DVT, together forms 
broader scope of venous 
thromboembolism (VTE). Intervention 
on pulmonary artery with local and 
directed thrombolysis has been an 
area of increasing interest. With 
systemic thrombolysis, the drug 
infused will be shunted towards 
unobstructerd pulmonary artery, thus 
limiting drug efficacy. On the contrary, 
catheter-directed thrombolysis promise 
more targeted therapy. Catheter 
available for thrombolysis were not 
design specifically for PE, instead for 
peripheral vasculature. 
Combination CDT and 
thromboaspiration or mechanical 
thrombectomy is the treatment of 
choice for this condition. Other  
interventional option for patient with 
absolute contraindication to thrombo-
lysis includes: thrombus fragmentation 
with pigtail or balloon catheter, 
rheolyticthrombectomy with hydro-
dynamic catheter device, suction 
thrombectomy with aspiration catheter 
and rotational thrombectomy. 
 ULTIMA (Ultrasound Acce-
lerated Thrombolysis of Pulmonary 
Embolism) trial using ultrasound-
assisted catheter-directed thrombo-
lysis (USAT) randomized 59 patients 
with intermediate risk of PE to USAT 
versus heparin anticoagulation. The 
USAT arm used gradual targeted 
infusion of thrombolysis over 12 to 24 
hour with alteplase dose of 1 mg/h. 
Patients in the USAT arm was better in 
right ventricle/left ventricle ratio at 24 
hour but the 90 day difference 
between USAT and heparin was 
statistically insignificant (p=0.07) 
suggesting an early advantage to 
USAT but not in the long term.16 
AngioJet used in DVT can also be the 
alternative to perform endovascular 
intervention in PE. Several case series 
reported that AngioJet procedure can 
induce bradycardia, hypotension, 
hypoxia, and hemodynamic collapse 
probably driven by release of 
vasoactive agents such as adenosine 
and bradykinin.17 Availabe data is still 
limited to support routine use of 
endovascular intervention in 
intermediate-high risk PE. 
 
Chronic venous insufficiency 
(CVI) 
A CVI is a pathological 
condition of the vein that implicated 
from prolonged stasis of venous blood 
flow. Venous hypertension gives rise 
to the chronic inflammation, edema, 
hyperpigmentation, eczema, 
lipodermatosclerosis, and ulcers.4 
Varices of the lower limbs is a very 
occuring disease in adult with 
prevalence 5-15% among men and 3-
29% among women. Lifestyle changes 
such as weight loss, diet, regular 
exercise, and elevation of the feet in 
the afternoon are the initial 
conservative therapy. For smaller 
veins, sclerotherapy is the treatment of 
choice. It is one of the most regularly 
procedure performed with injection of 
chemical irritant to induce 
thrombopheblitis, occlusion, and vein 
fibrosis. Another procedure is 
phlebectomy whiche remove tributary 
veins through multiple skin incision. 
This performed with local anesthesia 
such as with lidocaine which after 
procedure completed patient used 
compression stocking for 1-2 weeks.18  
 
Endovascular laser therapy 
(EVLT) 
An EVLT is the latest and most 
recent breakthrough treatment for 
chronic venous insufficiency. It is 
generally considered after treatment 
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with conservative therapy has failed. It 
works by ablating the innermost wall of 
the vein and induce direct heating 
effects. The lasers consist of continous 
and pulsed wave with the pulsed is 
more powerful than the first. The target 
for chromophore was the 810 nm and 
940 nm laser. Treatment with EVLT 
started with color doppler USG to map 
areas of  venous reflux then using 
guide wire to the target vein 
subsequently by the insertion of the 
laser energy tip. Once the laser is well 
positioned, it is activated and the laser 
fibre pulled back. Patients then use 
compression stockings to reduce 
complications such as tenderness and 
venous thromboembolism, are 
encouraged to walk immediately and 
returned to daily activities witihin 
days.19  
 
Conclusion 
 Advancement in endovascular 
intervension of venous disease is very 
encouraging. Many different 
techniques are developed to match the 
prevalent nature of the disease. 
Catheter directed thrombolysis and it 
variances delivers more promising 
future for treatment of DVT although 
more scientific studies for pulmonary 
embolism is needed. Less drug dose 
is needed so less bleeding compli-
cation are found with catheter directed 
thrombolysis. An EVLT are contem-
porary management for CVI using 
laser heat to ablate dysfunctional and 
varicose veins. It gives less 
complication with favorable outcome 
compared to surgical management. 
 
References 
 
1. Raskob G.F., Angchaisuksiri P., 
Blanco A.N. 2014. Thrombosis: a 
major contributor to global disease 
burden. Arterioscler Thromb Vasc 
Biol, ;342363-71.  
2. Di Nisio M., Van Es N.M, Buller 
H.R. 2017. Deep vein thrombosis 
and pulmonary embolism. Lancet, 
388:3060-3073. 
3. Bauersachs R., Berkowitz S.D., 
Brenner B., Buller H.R., Decousus 
H., Gallus A., et al. 2010. Oral 
rivaroxaban for symptomatic 
venous thromboembolism. N Engl 
J Med, 363:2499–2510. 
4. Bradbury A., Evans C., Allan P., 
Lee A., Ruckley C.V., Fowkes 
F.G. 1999. What are the 
symptoms of varicose veins? 
Edinburgh vein study cross 
sectional population survey. BMJ, 
318:353-356.  
5. Kahn S.R., Shbaklo H., Lamping 
D.L., Holcroft C.A., Shrier I., Miron 
M.J.,, et al. 2008. Determinants of 
health-related quality of life during 
the 2 years following deep vein 
thrombosis. J Thromb Haemost, 
6:1105-1112. 
6. Deroo S., Deatrick K.B., Henke 
P.K. 2010. The vessel wall: A 
forgotten player in post throm- 
botic syndrome. Thromb 
Haemost, 104:681–692.  
7. Prandoni P., Frulla M., Sartor D., 
Concolato A., Girolami A. 2005. 
Vein abnormalities and the post-
thrombotic syndrome. J Thromb 
Haemost , 3:401-402.  
8. Vedantham S., Thorpe P.E., 
Cardella J.F., Grassi C.J., Patel 
N.H., Ferral H., et al. 2006. 
Quality improvement guidelines 
for the treatment of lower 
extremity deep vein thrombosis 
with useof endovascular thrombus 
removal. J Vasc Interv Radiol, 
17:435–447.  
9. Lee K.A., Ramaswamy R.S. 2017. 
Interventional approaches to deep 
Hariawan, 2019              ACI (Acta Cardiologia Indonesiana) Vol.5 No.1(P):52-57  
 
57 
 
venous thrombosis. Curr Opin 
Cardiol, 32:679-686.  
10. Semba C.P., Dake M.D. 1994. 
Iliofemoral deep venous 
thrombosis: aggressive therapy 
with catheter-directed thrombo-
lysis. Radiology, 191:487–494.  
11. Sista A.K., Vedantham S., 
Kaufman J.A., Madoff D.C. 2015. 
Endovascular intervention for 
acute  and chronic lower extremity 
deep venous disease: State of the 
art. Radiology, 276:315-352. 
12. Mewissen M.W., Seabrook G.R., 
Meissner M.H., Cynamon J., 
Labropoulos N., Haughton S.H. 
1999. Catheter-directed thrombo-
lysis for lower extremity deep 
venous thrombosis: report of a 
national multicenter registry. 
Radiology, 211:39–49.  
13. Kim H.S., Patra A., Paxton B.E., 
Khan J., Streiff M.B. 2006. 
Adjunctive percutaneous 
mechanical thrombectomy for 
lower-extremity deep vein 
thrombosis: clinical and economic 
outcomes. J Vasc Interv Radiol, 
17:1099–1104.  
14. Cynamon J., Stein E.G., Dym 
R.J., Jagust M.B., Binkert C.A., 
Baum R.A. 2006. A new method 
for aggressive management of 
deep vein thrombosis: 
retrospective study of the power 
pulse technique. J Vasc Interv 
Radiol, 17:1043–1049.  
15. Patterson B.O., Hinchliffe R., 
Loftus I.M. 2010. Indications for 
catheter-directed thrombolisis in 
the management of acute 
proximal deep venous thrombosis, 
Arteriorscler Thromb Vasc Biol, 
30:669-674. 
16. Kucher N., Boekstegers P., Müller 
O.J., Kupatt C., Beyer-Westendorf 
J., Heitzer T., et al. 2014. 
Randomized, controlled trial of 
ultrasoundassisted catheter-
directed thrombolysis for acute 
intermediate-risk pulmonary 
embolism. Circulation, 129:479-
486. 
17. Zhu D.W. 2008. The potential 
mechanisms of bradyarrhythmias 
associated with AngioJet 
thrombectomy. J Invasive Cardiol, 
20:2A-4A 
18. Sadick N.S. 2006. Advances in 
the treatment of varicose veins: 
ambulatory phlebectomy, foam 
sclerotherapy, endovascular laser, 
and radiofrequency closure. Adv 
Dermatol, 22:139-156.  
19. Darwood R.J., Gough M.J. 2009. 
Endovenous laser treatment for 
uncomplicated varicose veins. 
Phlebology,  24:50-61.  
 
 
 
